journal article·2023-09-12Open access

Human Immunodeficiency Virus 1 Preferentially Fuses with pH-Neutral Endocytic Vesicles in Cell Lines and Human Primary CD4+ T-Cells

Manish Sharma, Mariana Marin, Hui Wu, David Prikryl, Gregory B. Melikyan

ACS Nano· Volume 17· Issue 17

Abstract

Despite extensive efforts, the principal sites of productive HIV-1 entry in different target cells─plasma membrane (PM) vs endosomes─remain controversial. To delineate the site(s) of HIV-1 fusion, we implemented a triple labeling approach that involves tagging pseudoviruses with the fluid-phase viral content marker, iCherry, the viral membrane marker, DiD, and the extraviral pH sensor, ecliptic pHluorin. The viral content marker iCherry is released into the cytoplasm upon virus-cell fusion irrespective of the sites of fusion. In contrast, the extent of dilution of the membrane marker upon fusion with the PM (loss of signal) vs the endosomal membrane (no change in punctate DiD appearance) discriminates between the principal sites of viral fusion. Additionally, ecliptic pHluorin incorporated into the viral membrane reports whether virus fusion occurs in acidic endosomes. Real-time single virus imaging in living HeLa-derived cells, a CD4+ T-cell line, and activated primary human CD4+ T-cells revealed a strong (80-90%) HIV-1 preference for fusion with endosomes. Intriguingly, we observed HIV-1 fusion only with pH-neutral intracellular vesicles and never with acidified endosomes. These endocytic fusion events are likely culminating in productive infection since endocytic inhibitors, such as EIPA, Pitstop2, and Dynasore, as well as a dominant-negative dynamin-2 mutant, inhibited HIV-1 infection in HeLa-derived and primary CD4+ T-cells. Furthermore, the inhibition of endocytosis in HeLa-derived cells promoted hemifusion at the PM but abrogated complete fusion. Collectively, these data reveal that the primary HIV-1 entry pathway in diverse cell types is through fusion with pH-neutral intracellular vesicles.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: HIV Research and Treatment · Cytomegalovirus and herpesvirus research · Mosquito-borne diseases and control

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia 30322, United States

Children’s Healthcare of Atlanta, Atlanta, Georgia 30322, United States

Funding

National Institute of Allergy and Infectious Diseases

References (52)

Show source-provided references
1. 10.1101/gad.83330010.1101/gad.833300 ↗
2. 10.1007/978-1-4614-0980-9_1010.1007/978-1-4614-0980-9_10 ↗
3. 10.1016/j.tim.2010.09.00310.1016/j.tim.2010.09.003 ↗
4. 10.1016/B978-0-12-385891-7.00004-010.1016/B978-0-12-385891-7.00004-0 ↗
5. 10.1016/0092-8674(87)90542-310.1016/0092-8674(87)90542-3 ↗
6. 10.1002/j.1460-2075.1988.tb02839.x10.1002/j.1460-2075.1988.tb02839.x ↗
7. 10.1016/S0092-8674(88)91241-X10.1016/S0092-8674(88)91241-X ↗
8. 10.1083/jcb.20030400810.1083/jcb.200304008 ↗
9. 10.1083/jcb.151.2.F910.1083/jcb.151.2.F9 ↗
10. 10.1128/jvi.68.2.1179-1185.199410.1128/jvi.68.2.1179-1185.1994 ↗
11. 10.1128/JVI.01543-1410.1128/JVI.01543-14 ↗
12. 10.1074/jbc.M10823220010.1074/jbc.M108232200 ↗
13. 10.1111/tra.1248110.1111/tra.12481 ↗
14. 10.1128/JVI.79.3.1581-1594.200510.1128/JVI.79.3.1581-1594.2005 ↗
15. 10.1016/j.cell.2009.02.04610.1016/j.cell.2009.02.046 ↗
16. 10.1016/j.cell.2011.06.02510.1016/j.cell.2011.06.025 ↗
17. 10.1128/JVI.79.9.5705-5712.200510.1128/JVI.79.9.5705-5712.2005 ↗
18. 10.1128/JVI.76.22.11440-11446.200210.1128/JVI.76.22.11440-11446.2002 ↗
19. 10.1128/JVI.75.22.11166-11177.200110.1128/JVI.75.22.11166-11177.2001 ↗
20. 10.1128/JVI.78.8.4120-4133.200410.1128/JVI.78.8.4120-4133.2004 ↗
21. 10.3390/v1102010010.3390/v11020100 ↗
22. 10.1016/j.chom.2011.10.01510.1016/j.chom.2011.10.015 ↗
23. 10.1371/journal.pone.007100210.1371/journal.pone.0071002 ↗
24. 10.1371/journal.pone.014894410.1371/journal.pone.0148944 ↗
25. 10.1042/BJ2010158810.1042/BJ20101588 ↗
26. 10.1074/jbc.M117.81808810.1074/jbc.M117.818088 ↗
27. 10.1128/AAC.00513-1310.1128/AAC.00513-13 ↗
28. 10.1021/acs.biochem.5b0102110.1021/acs.biochem.5b01021 ↗
29. 10.1073/pnas.161888311410.1073/pnas.1618883114 ↗
30. 10.1016/S0042-6822(03)00146-610.1016/S0042-6822(03)00146-6 ↗
31. 10.1128/AAC.46.6.1896-1905.200210.1128/AAC.46.6.1896-1905.2002 ↗
32. 10.1128/JVI.73.11.8966-8974.199910.1128/JVI.73.11.8966-8974.1999 ↗
33. 10.1111/bph.1442910.1111/bph.14429 ↗
34. 10.1186/1476-4598-12-410.1186/1476-4598-12-4 ↗
35. 10.1016/S0076-6879(07)38006-310.1016/S0076-6879(07)38006-3 ↗
36. 10.1038/nprot.2014.00410.1038/nprot.2014.004 ↗
37. Mabry R. L. · Ear Nose Throat J. · 1990 · 69 · 63
38. 10.1242/jcs.13857810.1242/jcs.138578 ↗
39. 10.1091/mbc.12.9.257810.1091/mbc.12.9.2578 ↗
40. 10.1128/JVI.01088-0710.1128/JVI.01088-07 ↗
41. 10.1371/journal.ppat.101062510.1371/journal.ppat.1010625 ↗
42. 10.1038/s41589-018-0213-210.1038/s41589-018-0213-2 ↗
43. 10.3390/biom1306093710.3390/biom13060937 ↗
44. 10.1016/j.stem.2018.10.00810.1016/j.stem.2018.10.008 ↗
45. 10.1371/journal.ppat.100404810.1371/journal.ppat.1004048 ↗
46. 10.1073/pnas.060762210410.1073/pnas.0607622104 ↗
47. 10.1016/j.virol.2010.10.01810.1016/j.virol.2010.10.018 ↗
48. 10.1128/JVI.00815-1310.1128/JVI.00815-13 ↗
49. 10.1186/1742-4690-8-9910.1186/1742-4690-8-99 ↗
50. 10.1007/s12250-014-3476-010.1007/s12250-014-3476-0 ↗
51. 10.1371/journal.ppat.100343110.1371/journal.ppat.1003431 ↗
52. 10.1016/j.vaccine.2007.09.01610.1016/j.vaccine.2007.09.016 ↗